TENAX THERAPEUTICS, INC. (TENX)
$2.15-$0.04 (-1.92%) Today
Stuart Rich - OfficerStuart Rich - OfficerStuart Rich - OfficerTenax Therapeutics Inc is a phase three, development-stage pharmaceutical company focused on identifying and developing therapeutics that address cardiovascular and pulmonary diseases with high unmet medical need, with an initial therapeutic focus on pulmonary hypertension. Its drug development pipeline comprises: Levosimendan, a novel, first-in-class K-ATP activator and calcium sensitizer developed for intravenous use in hospitalized patients with acutely decompensated heart failure; and Imatinib, as a potential therapy for pulmonary arterial hypertension. The company is currently conducting clinical trials only for levosimendan as its prioritized product candidate to evaluate its potential to help patients with pulmonary hypertension.
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market purchase | 3 | 1,025,867 | $1.81M |
| Option exercise | 4 | 17,438 |
Dollar totals are shown for open-market purchases and sales only. Grants, option exercises, gifts and tax withholding are reported by share count because they are not trades at a market price.
20 Form 4 filings on record, the earliest from Dec 12, 2024, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| ADAR1 Capital Management, LLC - 10% Owner | Open-market purchase | Common Stock | 202,124 | $1.78 | $360K | |
| ADAR1 Capital Management, LLC - 10% Owner | Open-market purchase | Common Stock | 716,369 | $1.77 | $1.27M | |
| ADAR1 Capital Management, LLC - 10% Owner | Open-market purchase | Common Stock | 107,374 | $1.75 | $188K | |
| Christopher Thomas Giordano - Officer | Option exercise | Stock Option (right to buy) | 8,500 | $0.00 | - | |
| Christopher Thomas Giordano - Officer | Option exercise | Common Stock | 219 | $3.55 | $777 | |
| Christopher Thomas Giordano - Officer | Option exercise | Common Stock | 8,500 | $5.94 | $50K | |
| Christopher Thomas Giordano - Officer | Option exercise | Stock Option (right to buy) | 219 | $0.00 | - | |
 Thomas R. Staab II - Officer | Grant or award | Common Stock | 10,000 | $0.00 | - | |
| Thomas R. Staab II - Officer | Grant or award | Stock Option (right to buy) | 450,000 | $0.00 | - | |
| Thomas McGauley - Officer | Option exercise | Stock Option (right to buy) | 50,000 | $0.00 | - | |
| Stuart Rich - Officer | Open-market purchase | Common Stock | 1,000 | $9.01 | $9K | |
| Stuart Rich - Officer | Open-market purchase | Common Stock | 1,500 | $9.08 | $14K | |
| Stuart Rich - Officer | Open-market purchase | Common Stock | 2,500 | $9.20 | $23K | |
| Christopher Thomas Giordano - Officer | Open-market purchase | Common Stock | 538 | $7.59 | $4K | |
| Christopher Thomas Giordano - Officer | Open-market purchase | Common Stock | 1,612 | $7.75 | $13K | |
| Christopher Thomas Giordano - Officer | Open-market purchase | Common Stock | 455 | $7.51 | $3K | |
 June Sherie Almenoff - Director | Open-market purchase | Common Stock | 93 | $7.15 | $665 | |
| June Sherie Almenoff - Director | Open-market purchase | Common Stock | 1,900 | $7.52 | $14K | |
| Thomas McGauley - Officer | Open-market purchase | Common Stock | 5,000 | $7.23 | $36K | |
| Thomas McGauley - Officer | Open-market purchase | Common Stock | 2,000 | $7.34 | $15K | |
| Thomas McGauley - Officer | Open-market purchase | Common Stock | 1,000 | $7.35 | $7K | |
| Gerald T. Proehl | Grant or award | Stock Option (right to buy) | 80,000 | $0.00 | - | |
| June Sherie Almenoff | Grant or award | Stock Option (right to buy) | 80,000 | $0.00 | - | |
| Michael H. Davidson | Grant or award | Stock Option (right to buy) | 80,000 | $0.00 | - | |
| Declan Doogan | Grant or award | Stock Option (right to buy) | 80,000 | $0.00 | - | |
| Robyn Hunter | Grant or award | Stock Option (right to buy) | 80,000 | $0.00 | - | |
| Robyn Hunter | Grant or award | Stock Option (right to buy) | 100,000 | $0.00 | - | |
| Declan Doogan | Grant or award | Stock Option (right to buy) | 100,000 | $0.00 | - | |
| Michael H. Davidson | Grant or award | Stock Option (right to buy) | 100,000 | $0.00 | - | |
| Christopher Thomas Giordano - Officer | Grant or award | Stock Option (right to buy) | 1,250,000 | $0.00 | - | |
| Stuart Rich - Officer | Grant or award | Stock Option (right to buy) | 500,000 | $0.00 | - | |
| Gerald T. Proehl | Grant or award | Stock Option (right to buy) | 100,000 | $0.00 | - | |
| June Sherie Almenoff | Grant or award | Stock Option (right to buy) | 100,000 | $0.00 | - |
TENAX THERAPEUTICS, INC. (TENX) had 2 insider filings in the last 90 days, with the most recent on 2026-08-24. The full record for TENX runs to 20 Form 4 filings, the earliest from 2024-12-12. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
3 insider purchases of TENX were filed in the last 90 days, totaling $1.81M.
No insider sales of TENX were filed in the last 90 days.
This page tracks TENX Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add TENX to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
